
If the FDA approves the treatment, it will be the first-ever MDMA-assisted therapy and psychedelic-assisted therapy. The PDUFA date is set for August 11, 2024.

If the FDA approves the treatment, it will be the first-ever MDMA-assisted therapy and psychedelic-assisted therapy. The PDUFA date is set for August 11, 2024.

Your daily dose of the clinical news you may have missed.

Access to methadone and buprenorphine treatment may be easier and incentive to continue treatment could start at home, using telehealth, according to HHS.

Eating disorders among US youth spiked during the COVID-19 pandemic, but a new study shows hospitalizations have been inching up for a decade or more.

The risk of cough and asthma in persons with severe depression was 3.32 times and 2.84 times higher, respectively, than that in those without depression, reported researchers.

The investigational combination opioid from Ensysce Biosciences is designed to deter abuse as well as prevent accidental or intentional overdose, the company said.

Already high rates of readmission and mortality at 30 days rose significantly higher at 90 days, according to this National Readmissions Database review.

Vacation behavior among US physicians was found wanting, with more than half taking less than 15 days/year, 20% taking ≤5 days, and 70% working on their time off.

This second shelf-life extension for the OTC naloxone hydrochloride 4 mg spray continues the FDA's campaign to prevent drug overdose and related fatalities.

The injured dancer needs to perform on closing night; the physiatrist may need to securely tape an ankle in exchange for a promise that this performance will be the last for a while.

Speaking about treating mental health symptoms linked to COVID-19 infection, Dr Abby Cheng reiterates the importance of validating the patient's experience.

Is the patient's low energy related to long COVID-related depression, post-exertional malaise, both? The differential diagnosis is all about nuance, says physiatrist Cheng.

Physiatrist Abby Cheng, MD, an author of the AAPM&R Long COVID Mental Health Consensus Guidance Statement, discusses why the symptoms can be confusing.

The risk of cardiovascular disease increased with longer cumulative exposure to ADHD medications, peaking at 3 to 5 years of use, reported researchers.

Individuals assessed for GDM whose time above target level was greater than 10% by CGM measure had a 63% increased risk of poor newborn outcomes.

Nearly half of survey respondents say they are anxious before seeing a doctor and, mainly because the do not have enough information to prepare for the visits.

When a patient is upset, agitated, or potentially violent, being empathetic and respectful are keys to defusing a potentially dangerous situation, says the Crisis Prevention Institute.

Your daily dose of the clinical news you may have missed.

Telehealth use is waning consistently from its peak use during the pandemic, raising the question of what the future holds for virtual care.

Results of a new study showed that greater intake of ultraprocessed foods, particularly artificial sweeteners and artificially sweetened beverages, was linked to a higher risk for depression.

Elevated inflammation, rather than depression, may drive poor weight loss outcomes in patients with obesity following bariatric surgery, suggest authors of new study.

Results from a new study suggest that postnatal SSRI treatment may be beneficial in the long term for both women with postpartum depression and their children.

The US FDA approved zuranolone 50 mg as the first oral, once-daily treatment for postpartum depression in adults.

Gen Z is most likely to use social media to self diagnose and YouTube is the top platform for diagnosis content; there is so much more to learn from this survey.

AspyreRx™, prescribed in 90-day increments, resulted in a mean HbA1c reduction of 1.3% at 180 days in 1 out of 2 phase 3 trial participants. A Q4 launch is anticipated.